Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-970 in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
NCT07645690Phase 1Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET-970 in clear cell renal cell carcinoma (ccRCC), sponsored by Chinese PLA General Hospital. Primary endpoints: Dose limited toxicity at 28 days, Incidence and severity of Adverse Events and Serious Adverse Events at 52 weeks and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
ET-970
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT07645690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07645690.